Upgrade to SI Premium - Free Trial

Cowen Said FDA Briefing Docs on Biogen (BIIB) Adu 'Not Without Controversy', Citing Statistical Reviewer

November 4, 2020 11:25 AM
Cowen analyst Phil Nadeau said that while the FDA briefing docs on Biogen's (NASDAQ: BIIB) Adu were positive, they were ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Trader Talk